Vancomycin Infiltrate-Induced Dermatitis Mimicking Bullous Cellulitis

REFERENCES

1. Reynolds, PE. Structure, biochemistry and mechanism of action of glycopeptide antibiotics. Euro J Clin Microbiol Infect Dis. 1989;8:943-950.
2. Geraci JE. Vancomycin. Mayo Clin Proc. 1977;52:631-634.
3. Vancomycin [product insert]. Lake Forest, IL: Hospira, Inc; 2010.
4. Le A, Patel S. Extravasation of noncytotoxic drugs: A review of the literature. Ann Pharmacother. 2014;48:870-886.
5. Levine DP. Vancomycin: a history. Clin Infect Dis. 2006;42 Suppl 1:S5-12.
6. Moellering RC Jr. Vancomycin: A 50-year reassessment. Clin Infect Dis. 2006;42 Suppl 1:S3-4.
7. Pitsiouu G, Kioumis I, Zarogoulidis K, et al. Prophylactic antibiotic administration for post cardiothoracic surgery sternal wounds: A retrospective study. Ann Transl Med. 2015;3:56-62.
8. Polk RE, Healy DP, Schwartz LB, et al. Vancomycin and the red-man syndrome: Pharmacodynamics of histamine release. J Infect Dis. 1988;157:502-507.
9. Laurencin CT, Horan RF, Senatus PB, et al. Stevens-Johnson-type reaction with vancomycin treatment. Ann Pharmacother. 1992;26:1520-1521.
10. Vidal C, González Quintela A, Fuente R. Toxic epidermal necrolysis due to vancomycin. Ann Allergy. 1992;68:345-347.
11. Felix-Getzik E, Sylvia LM. Vancomycin-induced leukocytoclastic vasculitis. Pharmacotherapy. 2009;29:846-851.
12. Young S, Ojaimi S, Dunckley H, et al. Vancomycin-associated drug reaction with eosinophilia and systemic symptoms syndrome. Intern Med J. 2014;44:694-696.
13. Nousari HC, Costarangos C, Anhalt GJ. Vancomycin-associated linear IgA bullous dermatosis. Ann Intern Med. 1998;129:507-508.
14. Hoelen DWM, Than DHT, van Vugt R, et al. Severe local vancomycin induced skin necrosis. Br J Clin Pharmacol. 2007;64:553-554.
15. Bohm NM, Wong JG. Bullous dermatosis associated with vancomycin extravasation. Am J Med Sci. 2012;343:177-179.
16. Medusa NHS Wales. Management of extravasation: Treatment summary. Available at: http://medusa.wales.nhs.uk/Docs/TreatmentSummaryPoster.pdf. Accessed January 17, 2016.
17. Hurst S, McMillan M. Innovative solutions in critical care units: extravasation guidelines. Dimens Crit Care Nurs. 2004;23:125-128.
18. Reynolds PM, MacLaren R, Mueller SW, et al. Management of extravasation injuries: A focused evaluation of noncytotoxic medications. Pharmacotherapy. 2014;34:617-632.
19. Williams L, So J, Buchan A, et al. Management of extravasation policy. Manchester Cancer. Available at: http://manchestercancer.org/wp-content/uploads/2014/09/Extravasation_Sept20131.pdf. Accessed January 17, 2016.
20. Al-Benna S, O’Boyle C, Holley J. Extravasation injuries in adults. ISRN Dermatol. 2013;2013:856541.
21. Payne AS, Savarese DMF. Extravasation injury from chemotherapy and other non-antineoplastic vesicants. UpToDate. Available at: http://www.uptodate.com/contents/extravasation-injury-from-chemotherapy-and-other-non-antineoplastic-vesicants?source=search_result&search=noncytotoxic+agent+vesicant&selectedTitle=1%7E150. Accessed November 22, 2015.
22. Ciprofloxacin [product insert]. Lake Forest, IL: Hospira, Inc.; 2013.
23. Upton J, Mulliken JB, Murray JE. Major intravenous extravasation injuries. Am J Surg. 1979;137:497-506.
24. Acyclovir [product insert]. Richmond Hill, ON: Pharmaceutical Partners of Canada, Inc.; 2009.
25. Sulfamethoxazole and trimethoprim [drug label information]. Sellersville, PA: Teva Pharmaceuticals USA; 2013.
26. Ganciclovir [prescribing information]. South San Francisco, CA: Genentech USA, Inc.;2010.
27. Doxycycline [package insert]. Schaumburg, IL: APP Pharmaceuticals, LLC: 2008.
28. Guillet S, Zeller V, Dubée V, et al. Large cohort study of central venous catheter thrombosis during intravenous antibiotic therapy. Antimicrob Agents Chemother. 2015;60:36-43.
29. Hadaway L, Chamallas SN. Vancomycin: New perspectives on an old drug. J Infus Nurs. 2003;26:278-284.
30. Edwards J, Green P, Haase D. A blistering disease: Bullous erysipelas. CMAJ. 2006;175:244.

AUTHOR CORRESPONDENCE